CBER Reviewers To Remain Accessible Post-Merger, CDER Tells BLA Sponsors
Executive Summary
CBER product reviewers will remain accessible to biologics sponsors following the consolidation of the agency's drug and biologics centers, CDER Deputy Director Steven Galson said
You may also be interested in...
FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total
FDA closed out the first half of 2003 with nine new molecular entities and six major biologic approvals, putting the agency well ahead of where it was at the same time last year, according to an analysis by F-D-C Reports' Pharmaceutical Approvals Monthly
FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total
FDA closed out the first half of 2003 with nine new molecular entities and six major biologic approvals, putting the agency well ahead of where it was at the same time last year, according to an analysis by F-D-C Reports' Pharmaceutical Approvals Monthly
CBER/CDER Consolidation: Weiss Named Acting Director Of New ODE VI
CBER Office of Therapeutics Research & Review Acting Director Sharon Risso will continue to serve as the point person for biologics staff transition questions after the consolidation with FDA's drugs center